These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 6178592)

  • 1. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E; Trande P; Grottola A; Buttafoco P; Rebecchi AM; Stroffolini T; Callea F; Merighi A; Camellini L; Zoboli P; Cosenza R; Miglioli L; Loria P; Iori R; Carulli N; Manenti F
    Dig Dis Sci; 1996 Jun; 41(6):1241-7. PubMed ID: 8654159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical application of fibroblast interferon--an overview.
    Billiau A
    Med Oncol Tumor Pharmacother; 1984; 1(2):87-96. PubMed ID: 6400034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo.
    Rhodes J; Jones DH; Bleehen NM
    Clin Exp Immunol; 1983 Sep; 53(3):739-43. PubMed ID: 6311468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low doses of interferon alpha result in more effective clinical natural killer cell activation.
    Edwards BS; Merritt JA; Fuhlbrigge RC; Borden EC
    J Clin Invest; 1985 Jun; 75(6):1908-13. PubMed ID: 4008643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interferon system as a basis for antiviral therapy or prophylaxis.
    Billiau A
    Antiviral Res; 1985; Suppl 1():131-40. PubMed ID: 3936410
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase I trial of recombinant gamma interferon in patients with cancer.
    Foon KA; Sherwin SA; Abrams PG; Stevenson HC; Holmes P; Maluish AE; Oldham RK; Herberman RB
    Cancer Immunol Immunother; 1985; 20(3):193-7. PubMed ID: 3933818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy.
    Tentori L; Fuggetta MP; D'Atri S; Aquino A; Nunziata C; Roselli M; Ballatore P; Bonmassar E; De Vecchis L
    Cancer Immunol Immunother; 1987; 24(1):86-91. PubMed ID: 3815421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin 1 beta) from human leukocytes.
    van Damme J; Opdenakker G; de Ley M; Heremans H; Billiau A
    Clin Exp Immunol; 1986 Nov; 66(2):303-11. PubMed ID: 3493097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.
    Hokland M; Basse P; Justesen J; Hokland P
    Cancer Metastasis Rev; 1988 Nov; 7(3):193-207. PubMed ID: 2465842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.
    Wejstål R; Norkrans G; Weiland O; Schvarcz R; Fuchs D; Wachter H; Fryden A; Glaumann H
    Clin Exp Immunol; 1992 Mar; 87(3):340-5. PubMed ID: 1544220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effect of alpha and beta human interferons on some immunological parameters.
    Lucero MA; Magdelenat H; Fridman W; Pouillart P; Billardon C; Billiau A; Cantell K; Falcoff E
    Tex Rep Biol Med; 1981-1982; 41():427-34. PubMed ID: 6763364
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
    Reiter Z
    J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients.
    Lucero MA; Magdelenat H; Fridman WH; Pouillart P; Billardon C; Billiau A; Cantell K; Falcoff E
    Eur J Cancer Clin Oncol; 1982 Mar; 18(3):243-51. PubMed ID: 6178592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
    Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
    Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.